Begins Coverage on LivaNova (NASDAQ:LIVN) started coverage on shares of LivaNova (NASDAQ:LIVNGet Rating) in a research report report published on Thursday morning. The brokerage issued a buy rating on the stock.

Several other equities research analysts also recently weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of LivaNova from $73.00 to $63.00 and set a buy rating for the company in a research report on Wednesday, November 23rd. Barclays began coverage on shares of LivaNova in a report on Wednesday, December 21st. They issued an equal weight rating and a $62.00 price target for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from, the company presently has an average rating of Moderate Buy and a consensus target price of $76.20.

LivaNova Stock Performance

LIVN opened at $42.71 on Thursday. The company has a 50-day moving average of $52.02 and a 200-day moving average of $52.02. LivaNova has a 1-year low of $40.26 and a 1-year high of $88.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.98 and a quick ratio of 2.54.

LivaNova (NASDAQ:LIVNGet Rating) last released its earnings results on Wednesday, February 22nd. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.09. The company had revenue of $274.90 million during the quarter, compared to the consensus estimate of $262.16 million. LivaNova had a negative net margin of 8.44% and a positive return on equity of 10.49%. The company’s revenue was up 1.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.57 EPS. As a group, analysts forecast that LivaNova will post 2.58 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Western Pacific Wealth Management LP acquired a new position in LivaNova during the 3rd quarter valued at about $44,000. Point72 Middle East FZE acquired a new position in LivaNova during the 4th quarter valued at about $72,000. Picton Mahoney Asset Management acquired a new position in LivaNova during the 3rd quarter valued at about $70,000. Wolverine Asset Management LLC boosted its stake in LivaNova by 35.3% during the 3rd quarter. Wolverine Asset Management LLC now owns 1,454 shares of the company’s stock valued at $73,000 after purchasing an additional 379 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new position in LivaNova during the 3rd quarter valued at about $85,000. 98.89% of the stock is owned by institutional investors and hedge funds.

About LivaNova

(Get Rating)

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiopulmonary and Other segments. The Cardiopulmonary segment is involved in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories.

Recommended Stories

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with's FREE daily email newsletter.